Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Metabolisms

  • 525 Articles
  • 2 Posts
  • ← Previous
  • 1
  • 2
  • …
  • 51
  • 52
  • 53
  • Next →
Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
Kimihiko Matsusue, … , Marc L. Reitman, Frank J. Gonzalez
Kimihiko Matsusue, … , Marc L. Reitman, Frank J. Gonzalez
Published March 1, 2003
Citation Information: J Clin Invest. 2003;111(5):737-747. https://doi.org/10.1172/JCI17223.
View: Text | PDF

Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

  • Text
  • PDF
Abstract

To elucidate the function of PPARγ in leptin-deficient mouse (ob/ob) liver, a PPARγ liver-null mouse on an ob/ob background, ob/ob-PPARγ(fl/fl)AlbCre+, was produced using a floxed PPARγ allele, PPARγ(fl/fl), and Cre recombinase under control of the albumin promoter (AlbCre). The liver of ob/ob-PPARγ(fl/fl)AlbCre+ mice had a deletion of exon 2 and a corresponding loss of full-length PPARγ mRNA and protein. The PPARγ-deficient liver in ob/ob mice was smaller and had a dramatically decreased triglyceride (TG) content compared with equivalent mice lacking the AlbCre transgene (ob/ob-PPARγ(fl/fl)AlbCre–). Messenger RNA levels of the hepatic lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, and stearoyl-CoA desaturase-1, were reduced in ob/ob-PPARγ(fl/fl)AlbCre+ mice, and the levels of serum TG and FFA in ob/ob-PPARγ(fl/fl)AlbCre+ mice were significantly higher than in the control ob/ob-PPARγ(fl/fl)AlbCre– mice. Rosiglitazone treatment exacerbated the fatty liver in ob/ob-PPARγ(fl/fl)AlbCre– mice compared with livers from nonobese Cre– mice; there was no effect of rosiglitazone in ob/ob-PPARγ(fl/fl)AlbCre+ mice. The deficiency of hepatic PPARγ further aggravated the severity of diabetes in ob/ob mice due to decreased insulin sensitivity in muscle and fat. These data indicate that hepatic PPARγ plays a critical role in the regulation of TG content and in the homeostasis of blood glucose and insulin resistance in steatotic diabetic mice.

Authors

Kimihiko Matsusue, Martin Haluzik, Gilles Lambert, Sun-Hee Yim, Oksana Gavrilova, Jerrold M. Ward, Bryan Brewer Jr., Marc L. Reitman, Frank J. Gonzalez

×

Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production
Simon J. Fisher, C. Ronald Kahn
Simon J. Fisher, C. Ronald Kahn
Published February 15, 2003
Citation Information: J Clin Invest. 2003;111(4):463-468. https://doi.org/10.1172/JCI16426.
View: Text | PDF

Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production

  • Text
  • PDF
Abstract

We and others have suggested that insulin predominantly acts indirectly to inhibit hepatic glucose production (HGP) via suppression of gluconeogenic precursors, FFAs, and glucagon. To test that hypothesis, we performed high-dose hyperinsulinemic-euglycemic clamps using [3-3H]-glucose in liver-specific insulin receptor knockout (LIRKO) mice, LIRKO mice treated with streptozotocin (LIRKO+STZ), and controls. In LIRKO mice, fasted glucose was normal, but insulin levels were elevated tenfold. STZ treatment reduced insulinemia by 60% with resulting hyperglycemia. Interestingly, basal HGP was similar in all three groups. During the clamp, HGP was suppressed by 82 ± 17% in controls, but was not suppressed in either LIRKO or LIRKO+STZ mice. Glucose infusion and utilization were impaired (∼50%) in LIRKO and LIRKO+STZ mice versus controls. Insulin suppressed FFAs similarly in all groups (∼46%). Glucagon was not significantly suppressed during the clamp. Thus, in LIRKO mice, (a) high-dose insulin fails to suppress HGP indicating that both direct and indirect effects of insulin require an intact insulin-signaling pathway in the liver; (b) primary hepatic insulin resistance leads to hyperinsulinemia and secondary extrahepatic insulin resistance; and (c) lowering insulin levels with STZ tended to improve extrahepatic insulin sensitivity but failed to reveal the previously postulated indirect role of insulin in suppressing HGP.

Authors

Simon J. Fisher, C. Ronald Kahn

×

Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo
Matthijs K.C. Hesselink, … , Esther Kornips, Patrick Schrauwen
Matthijs K.C. Hesselink, … , Esther Kornips, Patrick Schrauwen
Published February 15, 2003
Citation Information: J Clin Invest. 2003;111(4):479-486. https://doi.org/10.1172/JCI16653.
View: Text | PDF

Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo

  • Text
  • PDF
Abstract

Phosphocreatine (PCr) resynthesis rate following intense anoxic contraction can be used as a sensitive index of in vivo mitochondrial function. We examined the effect of a diet-induced increase in uncoupling protein 3 (UCP3) expression on postexercise PCr resynthesis in skeletal muscle. Nine healthy male volunteers undertook 20 one-legged maximal voluntary contractions with limb blood flow occluded to deplete muscle PCr stores. Exercise was performed following 7 days consumption of low-fat (LF) or high-fat (HF) diets. Immediately following exercise, blood flow was reinstated, and muscle was sampled after 20, 60, and 120 seconds of recovery. Mitochondrial coupling was assessed by determining the rate of PCr resynthesis during recovery. The HF diet increased UCP3 protein content by approximately 44% compared with the LF diet. However, this HF diet–induced increase in UCP3 expression was not associated with any changes in the rate of muscle PCr resynthesis during conditions of maximal flux through oxidative phosphorylation. Muscle acetylcarnitine, free-creatine, and lactate concentrations during recovery were unaffected by the HF diet. Taken together, our findings demonstrate that increasing muscle UCP3 expression does not diminish the rate of PCr resynthesis, allowing us to conclude that the primary role of UCP3 in humans is not uncoupling.

Authors

Matthijs K.C. Hesselink, Paul L. Greenhaff, Dimitru Constantin-Teodosiu, Eric Hultman, Wim H.M. Saris, Robby Nieuwlaat, Gert Schaart, Esther Kornips, Patrick Schrauwen

×

Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy
Nigel A. Calcutt, … , Lee L. Rubin, David R. Tomlinson
Nigel A. Calcutt, … , Lee L. Rubin, David R. Tomlinson
Published February 15, 2003
Citation Information: J Clin Invest. 2003;111(4):507-514. https://doi.org/10.1172/JCI15792.
View: Text | PDF

Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy

  • Text
  • PDF
Abstract

Hedgehog proteins modulate development and patterning of the embryonic nervous system. As expression of desert hedgehog and the hedgehog receptor, patched-1, persist in the postnatal and adult peripheral nerves, the hedgehog pathway may have a role in maturation and maintenance of the peripheral nervous system in normal and disease states. We measured desert hedgehog expression in the peripheral nerve of maturing diabetic rats and found that diabetes caused a significant reduction in desert hedgehog mRNA. Treating diabetic rats with a sonic hedgehog–IgG fusion protein fully restored motor- and sensory-nerve conduction velocities and maintained the axonal caliber of large myelinated fibers. Diabetes-induced deficits in retrograde transport of nerve growth factor and sciatic-nerve levels of calcitonin gene–related product and neuropeptide Y were also ameliorated by treatment with the sonic hedgehog–IgG fusion protein, as was thermal hypoalgesia in the paw. These studies implicate disruption of normal hedgehog function in the etiology of diabetes-induced peripheral-nerve dysfunction and indicate that delivery of exogenous hedgehog proteins may have therapeutic potential for the treatment of diabetic neuropathy.

Authors

Nigel A. Calcutt, Karen L. Allendoerfer, Andrew P. Mizisin, Alicia Middlemas, Jason D. Freshwater, Monica Burgers, Rigel Ranciato, Jean-Dominique Delcroix, Frederick R. Taylor, Renee Shapiro, Kathy Strauch, Henryk Dudek, Thomas M. Engber, Alphonse Galdes, Lee L. Rubin, David R. Tomlinson

×

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo
Weijun Jin, … , Jane M. Glick, Daniel J. Rader
Weijun Jin, … , Jane M. Glick, Daniel J. Rader
Published February 1, 2003
Citation Information: J Clin Invest. 2003;111(3):357-362. https://doi.org/10.1172/JCI16146.
View: Text | PDF

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo

  • Text
  • PDF
Abstract

Endothelial lipase (EL) is a recently discovered member of the lipoprotein lipase gene family that hydrolyzes HDL phospholipids ex vivo and reduces HDL cholesterol (HDL-C) levels when overexpressed in vivo in mice. To gain further insight into the physiological role of EL in the metabolism of HDL in vivo, studies were performed in which EL was inhibited in wild-type, hepatic lipase knockout (HL–/–), and human apoA-I transgenic mice by intravenous infusion of a polyclonal antibody inhibitory to murine EL. As compared with infusion of a control antibody, infusion of the inhibitory antibody resulted in a 25–60% increase in HDL-C levels in the three mouse models, with the peak HDL-C levels occurring at 48 hours after injection. Inhibition of EL also generated larger HDL particles in the HL–/– mice. The clearance of HDL phospholipid was significantly slower in human apoA-I transgenic mice injected with an antibody against murine EL (mEL) than in mice injected with a control antibody. We conclude that inhibition of EL results in increased HDL-C levels and that EL is an important enzyme in the physiological regulation of HDL metabolism.

Authors

Weijun Jin, John S. Millar, Uli Broedl, Jane M. Glick, Daniel J. Rader

×

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)
Kevan C. Herold, … , Mariela Glandt, Jeffrey A. Bluestone
Kevan C. Herold, … , Mariela Glandt, Jeffrey A. Bluestone
Published February 1, 2003
Citation Information: J Clin Invest. 2003;111(3):409-418. https://doi.org/10.1172/JCI16090.
View: Text | PDF

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

  • Text
  • PDF
Abstract

Dimeric Fc receptor (FcR) nonbinding anti-CD3 antibodies have been developed to minimize toxicities associated with classical anti-CD3 monoclonal antibodies (e.g., OKT3). Studies with murine analogs of non-FcR–binding antibodies have shown reduced mitogenicity compared to OKT3. In a trial of an FcR nonbinding humanized anti-CD3 mAb hOKT3γ1(Ala-Ala) for treatment of patients with type 1 diabetes, we found significant increases in IL-10 and IL-5 in the serum of 63% and 72% of patients, respectively, and TNF-α and IL-6 levels that were lower than those previously reported following OKT3 therapy. The activation signal delivered by hOKT3γ1(Ala-Ala) was associated with calcium signaling and cytokine production by previously activated human cells in vitro. However, the production of IL-10, compared to IFN-γ on a molar basis, was greater after culture with hOKT3γ1(Ala-Ala) than with OKT3. Flow cytometric studies confirmed that OKT3 induced IFN-γ and IL-10 production, but hOKT3γ1(Ala-Ala) induced only detectable IL-10 production in CD45RO+ cells. Moreover, in vivo, we found IL-10+CD4+ T cells after drug treatment. These cells were heterogeneous but generally CD45RO+, CTLA-4–, and expressed CCR4. A subgroup of these cells expressed TGF-β. Thus, the non-FcR binding anti-CD3 mAb, hOKT3γ1(Ala-Ala) delivers an activation signal to T cells that is quantitatively and qualitatively different from OKT3. It leads to the generation of T cells that might inhibit the autoimmune response and may be involved in the beneficial effect on β cell destruction in Type 1 diabetes.

Authors

Kevan C. Herold, Joshua B. Burton, Fleur Francois, Ena Poumian-Ruiz, Mariela Glandt, Jeffrey A. Bluestone

×

Adipose-derived resistin and gut-derived resistin-like molecule–β selectively impair insulin action on glucose production
Michael W. Rajala, … , Philipp E. Scherer, Luciano Rossetti
Michael W. Rajala, … , Philipp E. Scherer, Luciano Rossetti
Published January 15, 2003
Citation Information: J Clin Invest. 2003;111(2):225-230. https://doi.org/10.1172/JCI16521.
View: Text | PDF

Adipose-derived resistin and gut-derived resistin-like molecule–β selectively impair insulin action on glucose production

  • Text
  • PDF
Abstract

The adipose-derived hormone resistin is postulated to link obesity to insulin resistance and diabetes. Here, the infusion of either resistin or the resistin-like molecule–β (RELMβ) rapidly induced severe hepatic but not peripheral insulin resistance. In the presence of physiologic hyperinsulinemia, the infusion of purified recombinant resistin, increasing circulating resistin levels by approximately twofold to 15-fold, inhibited glucose metabolism such that lower rates of glucose infusion were required to maintain the plasma glucose concentration at basal levels. The effects of resistin and RELMβ on in vivo insulin action were completely accounted for by a marked increase in the rate of glucose production. These results support the notion that a novel family of fat- and gut-derived circulating proteins modulates hepatic insulin action.

Authors

Michael W. Rajala, Silvana Obici, Philipp E. Scherer, Luciano Rossetti

×

The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
Benoit Viollet, … , Rémy Burcelin, Sophie Vaulont
Benoit Viollet, … , Rémy Burcelin, Sophie Vaulont
Published January 1, 2003
Citation Information: J Clin Invest. 2003;111(1):91-98. https://doi.org/10.1172/JCI16567.
View: Text | PDF

The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity

  • Text
  • PDF
Abstract

AMP-activated protein kinase (AMPK) is viewed as a fuel sensor for glucose and lipid metabolism. To better understand the physiological role of AMPK, we generated a knockout mouse model in which the AMPKα2 catalytic subunit gene was inactivated. AMPKα2–/– mice presented high glucose levels in the fed period and during an oral glucose challenge associated with low insulin plasma levels. However, in isolated AMPKα2–/– pancreatic islets, glucose- and L-arginine–stimulated insulin secretion were not affected. AMPKα2–/– mice have reduced insulin-stimulated whole-body glucose utilization and muscle glycogen synthesis rates assessed in vivo by the hyperinsulinemic euglycemic clamp technique. Surprisingly, both parameters were not altered in mice expressing a dominant-negative mutant of AMPK in skeletal muscle. Furthermore, glucose transport was normal in incubated isolated AMPKα2–/– muscles. These data indicate that AMPKα2 in tissues other than skeletal muscles regulates insulin action. Concordantly, we found an increased daily urinary catecholamine excretion in AMPKα2–/– mice, suggesting altered function of the autonomic nervous system that could explain both the impaired insulin secretion and insulin sensitivity observed in vivo. Therefore, extramuscular AMPKα2 catalytic subunit is important for whole-body insulin action in vivo, probably through modulation of sympathetic nervous activity.

Authors

Benoit Viollet, Fabrizio Andreelli, Sebastian B. Jørgensen, Christophe Perrin, Alain Geloen, Daisy Flamez, James Mu, Claudia Lenzner, Olivier Baud, Myriam Bennoun, Emmanuel Gomas, Gaël Nicolas, Jørgen F.P. Wojtaszewski, Axel Kahn, David Carling, Frans C. Schuit, Morris J. Birnbaum, Erik A. Richter, Rémy Burcelin, Sophie Vaulont

×

Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype
Kazuhiko Takahashi, … , Tomoo Ishikawa, Hidehito Kotani
Kazuhiko Takahashi, … , Tomoo Ishikawa, Hidehito Kotani
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1791-1799. https://doi.org/10.1172/JCI15784.
View: Text | PDF

Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype

  • Text
  • PDF
Abstract

Research Article

Authors

Kazuhiko Takahashi, Hiroaki Suwa, Tomoo Ishikawa, Hidehito Kotani

×

The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth
Tadahiro Kitamura, … , Karen C. Arden, Domenico Accili
Tadahiro Kitamura, … , Karen C. Arden, Domenico Accili
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1839-1847. https://doi.org/10.1172/JCI16857.
View: Text | PDF

The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth

  • Text
  • PDF
Abstract

Research Article

Authors

Tadahiro Kitamura, Jun Nakae, Yukari Kitamura, Yoshiaki Kido, William H. Biggs III, Christopher V.E. Wright, Morris F. White, Karen C. Arden, Domenico Accili

×
  • ← Previous
  • 1
  • 2
  • …
  • 51
  • 52
  • 53
  • Next →
Using SORLA to sort out human obesity
Vanessa Schmidt and colleagues demonstrate that the intracellular sorting receptor SORLA is an important regulator of lipid metabolism…
Published June 20, 2016
Scientific Show StopperMetabolism

Intracellular calcium leak recasts β cell landscape
Gaetano Santulli and colleagues reveal that RyR2 calcium channels in pancreatic β cells mediate insulin release and glucose homeostasis…
Published April 6, 2015
Scientific Show StopperMetabolism
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts